Sign in
SGMO Stock Price, Chart, Stats & News
Sangamo Therapeutics, Inc.
Save
16.57M
Market cap
–
Current P/E
0.39x
Forward P/E
SGMO chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 100.00% |
Operating margin | -331.64% |
Pretax margin | -332.63% |
Net margin | -331.28% |
Effective tax rate | 0.40% |
ROA | -122.86% |
ROE | -813.95% |
D/E | 4.07x |
Interest coverage ratio | – |
SGMO valuation
P/E | – |
P/S | 3.63x |
P/B | 15.64x |
P/CF | -1.28x |
P/FCF | -1.56x |
P/OCF | -1.28x |
PEG | 0.02x |
EV multiple | -1.21x |
About
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company focused on transforming patient lives through the development of genomic medicines. The company leverages advanced platform technologies including gene therapy, cell therapy, genome editing, and genome regulation to achieve its objectives. A cornerstone of Sangamo's approach is its proprietary zinc finger protein (ZFP) technology platform.
Similar securities
Based on sector and market capitalization
Report issue